Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Gastroenterology. 2013 Feb 16;144(7):1530–1542.e12. doi: 10.1053/j.gastro.2013.02.009

Figure 3. Jag-1 mediates tumor-supporting propertied of YAP in HCC cells.

Figure 3

(A) Jag-1 and YAP expression and cell proliferation of PLC/PRF/5 cells after overexpression of Jag-1 and concomitant inhibition of YAP by gene-specific siRNA. Statistics compares Jag-1/scramble siRNA with Jag-1/YAP siRNA. (B) Jag-1, YAP, Hes-1 protein levels and proliferation of PLC/PRF/5 cells after overexpression YAPS127A and simultaneous Jag-1 silencing. Statistical testing compares Jag-1 siRNA and YAPS127A/Jag-1 siRNA. (C) Hes-1 expression and cell proliferation of PLC/PRF/5 cells after expression of YAP and concomitant administration of the Notch transcriptional complex inhibitor SAHM1. Statistics compared SAHM1 with YAP/SAHM1. For (A) and (B) untreated (control) and scramble siRNA-transfected cells served as controls. For (C) untreated and DMSO-treated cells were used as controls. For (A), (B), and (C), cell proliferation was measured 24, 48, and 72 h after transfection. Actin was used as loading control. Values represent means ± SD. Statistical test: Mann-Whitney U. n.s. - not significant, **p<0.01, ***p<0.001.